RUNX1T1 and acute myeloid leukemia: This is why the expression of CEBPA in AML patients has been extensively studied, and it has been shown to be downregulated by another driver of leukemogenesis, namely the AML-ETO fusion protein, which is present in 5–10% of patients with AML [42].